Myelo Therapeutics GmbH, a clinical-stage pharmaceutical company focused on developing therapies for cancer supportive care and medical countermeasures (MCM), announced today the successful closing of a multi-million Euro financing round, following...

Infection with the novel coronavirus SARS-CoV-2 follows a highly variable course: some of those infected do not even notice it, while others become so seriously ill that their lives are placed at risk. Scientists from the Berlin Institute of Health...

- Multiyear alliance underpins Randox commitment to increase biochip manufacturing to transform rapid diagnostic testing

- SCIENION AG to integrate its precision dispensing technology to enable Randox to scale-up Biochip manufacturing across the...

The history of the pharmaceutical company Takeda from Japan has been 239 years, for 39 years

Takeda is active in Germany. During this time it has acquired and developed the current locations in Berlin, Oranienburg, Konstanz and Singen. In...

The development of drugs for the treatment of rare diseases is difficult, as is the development of safe methods of diagnosis. Although the number of patients suffering from rare diseases is relatively large, the estimated 8,000 different rare...

In late January the Sars-Cov-2 pandemic officially arrived and started spreading across Germany. Since then – like in almost every other country globally - every new day feels completely new, uncertain and presents previously unknown challenges,...

At the beginning of 2019, the British foundation Wellcome Trust opened an office in Berlin, thus expanding its activities to Germany. The first project funded by the foundation in Germany is a translation partnership with the Berlin Institute of...

The pharmaceutical company Bayer wants to help turn Berlin into a biotech hub like Boston. This is possible, says head of research Stefan Oelrich in an interview with the Tagesspiegel.

Myelo Therapeutics GmbH, a clinical-stage pharmaceutical company focused on developing therapies for cancer supportive care and medical countermeasures (MCM), announced that it has been awarded a 3-year development contract valued at up to $6...

Repeats of individual building blocks within proteins are the cause of many hereditary diseases, but how such repeats actually cause disease is still largely unknown. Researchers in Berlin investigated how repeat elongations lead to the disease...